サンプル依頼リスト カート
  • English
  • Korean
表紙：膵臓がん診断市場-世界の産業規模、シェア、動向、機会、2018年～2028年予測
市場調査レポート
商品コード
1331403

膵臓がん診断市場-世界の産業規模、シェア、動向、機会、2018年～2028年予測

Pancreatic Cancer Diagnostics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Test Type, By Cancer Type, By End User, Region and Competition
出版日: | 発行: TechSci Research | ページ情報: 英文 113 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

膵臓がん診断市場-世界の産業規模、シェア、動向、機会、2018年～2028年予測
出版日: 2023年08月01日
発行: TechSci Research
ページ情報: 英文 113 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の膵臓がん診断市場は、膵臓がんの罹患率の増加、低侵襲診断法に対する需要の高まり、研究開発への投資の増加などを背景に、予測期間中に目覚ましい成長を遂げる見通しです。

膵臓がんに関する研究開発の増加

膵臓がんは、診断と治療が困難な攻撃性の高いがんです。しかし、最近の調査では、膵臓がん診断の分野で有望な発展が見られます。リキッドバイオプシー、人工知能、バイオマーカー、画像診断技術、個別化医療はすべて、最終的に膵がんの患者の転帰を改善する可能性のある活発な研究分野です。

リキッドバイオプシーは非侵襲的な診断ツールで、患者の血液中の循環腫瘍細胞（CTC）と無細胞DNA（cfDNA）を分析します。最近の調査では、リキッドバイオプシーを用いることで、従来の画像診断よりも早い段階で膵臓がんを発見できることが示されています。

人工知能（AI）は、既存の診断法の精度と効率を向上させるために、膵臓がん診断の分野で利用されています。最近の調査では、AIアルゴリズムが医用画像データに基づいて膵臓がんの可能性を正確に予測できることが示されています。2020年にJournal of Clinical Oncology誌に発表された研究では、AIアルゴリズムがCTスキャンに基づいて膵臓がんの可能性を90％の精度で予測できることがわかっています。

バイオマーカーとは、病気の存在を示すのに利用できる生体分子のことです。最近の調査では、膵臓がんの診断に有用なバイオマーカーがいくつか特定されています。2021年にJournal of Gastroenterology誌に発表された研究では、3つのバイオマーカー（CA19-9、CEA、FGF21）の組み合わせにより、膵嚢胞を有する患者における膵がんの可能性を正確に予測できることが判明しました。2020年にJournal of Proteome Research誌に発表された別の研究では、膵臓がんの早期発見に有用と思われるバイオマーカーがいくつか同定されました。

医用画像診断技術の進歩も膵臓がん診断を向上させています。最近の調査では、超音波内視鏡（EUS）が膵臓がんの検出において精度の高い画像診断技術であることが示されています。2020年にJournal of Gastroenterology誌に発表された研究では、疑わしい膵臓腫瘤のある患者において、EUSは94％の精度で膵臓がんを検出できることがわかっています。

個別化医療とは、個人の遺伝的体質に合わせた医療を行うことです。最近の調査では、個別化医療が膵臓がん診断に有用である可能性が示されています。2021年にJournal of the National Cancer Instituteに発表された研究では、個別化ワクチンは免疫系を刺激して膵臓がん細胞を攻撃させることができることがわかっています。

膵臓がんの有病率の増加

膵臓がんの有病率の増加は、膵臓がん診断市場に大きな影響を与える可能性が高いです。膵臓がんの罹患率が上昇を続ける中、治療が最も効果的な早期段階でこの疾患を発見するため、より優れた効率的な診断ツールの必要性が高まっています。

高齢化、2型糖尿病、肥満の増加、喫煙や飲酒などの不健康なライフスタイルの選択など、膵臓がんの有病率増加にはいくつかの要因があります。こうした動きは今後も続くと予想され、膵臓がん診断に対する需要の増加に拍車をかけています。

このような需要を受けて、膵臓がん診断市場は今後数年間で成長すると思われます。CTスキャン、MRIスキャン、PETスキャンなどの画像検査や、特定のバイオマーカーのレベルを測定する血液検査など、膵臓がんの診断ツールはすでにいくつかあります。しかし、特に早期の膵臓がんに対しては、より正確で信頼性の高い診断ツールが必要です。

血液中の循環腫瘍DNAを検出するリキッドバイオプシーや、膵臓のより詳細で正確な画像を提供できる新しい画像技術など、膵臓がんの新しい診断ツールを開発するための研究開発が進められています。

膵臓がんの有病率の増加は、研究者や企業がこの致命的な疾患を検出し治療するためのより良いツールの開発に取り組んでいるため、膵臓がん診断市場への技術革新と投資を促進すると考えられ、これが今後数年間の世界の膵臓がん診断市場の成長を支えると思われます。

利用可能なカスタマイズ

TechSci Research社は、所定の市場データを用いて、企業固有のニーズに応じたカスタマイズを提供しています。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 膵臓がん診断の世界市場展望

  • 市場規模と予測
    • 金額ベース
  • 市場シェアと予測
    • 検査タイプ別（画像診断、生検、血液検査、肝機能検査、その他）
    • がんタイプ別（外分泌がん、腺がん、扁平上皮がん、膠原がん、その他）
    • エンドユーザー別（病院、診断センター、その他）
    • 地域別
    • 企業別（2022年）
  • 製品マップ
    • 検査タイプ別
    • がんタイプ別
    • エンドユーザー別
    • 地域別

第6章 北米の膵臓がん診断市場の展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • 検査タイプ別
    • がんタイプ別
    • エンドユーザー別
    • 国別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の膵臓がん診断市場の展望

  • 市場規模および予測
    • 金額ベース
  • 市場シェアと予測
    • 検査タイプ別
    • がんタイプ別
    • エンドユーザー別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の膵臓がん診断市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • 検査タイプ別
    • がんタイプ別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の膵臓がん診断市場の展望

  • 市場規模および予測
    • 金額ベース
  • 市場シェアと予測
    • 検査タイプ別
    • がんタイプ別
    • エンドユーザー別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの膵臓がん診断市場の展望

  • 市場規模および予測
    • 金額ベース
  • 市場シェアと予測
    • 検査タイプ別
    • がんタイプ別
    • エンドユーザー別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の展開
  • 合併・買収
  • 製品発表

第13章 膵臓がん診断の世界市場SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Key Personnel
  • SWOT Analysis
    • Siemens Healthcare GmbH
    • FUJIFILM Corporation
    • Laboratory Corporation of America Holdings
    • Abbott Laboratories, Inc.
    • Agilent Technologies, Inc.
    • Thermo Fisher Scientific Inc.
    • Immunovia, Inc.

第16章 戦略的提言

目次
Product Code: 15209

Global Pancreatic Cancer Diagnostics Market is poised to grow at an impressive rate during the forecast period on account of the increasing incidence of pancreatic cancer, rising demand for minimally invasive diagnostic procedures, and growing investment in research and development.

Pancreatic cancer is a deadly disease that affects the pancreas, a vital organ located in the abdomen that plays a critical role in digestion and metabolism. Unfortunately, pancreatic cancer is notoriously difficult to detect in its early stages, and by the time it is diagnosed, it has often spread to other parts of the body. This is why early detection is critical to improving survival rates, and the demand for pancreatic cancer diagnostics has increased significantly in recent years.

One of the main factors that has increased the demand for pancreatic cancer diagnostics is the rising incidence of the disease. The increasing incidence of pancreatic cancer has led to a growing demand for diagnostic tests that can detect the disease in its early stages.

Another factor that has contributed to the demand for pancreatic cancer diagnostics is the aging population. The majority of instances of pancreatic cancer occur in those over 60, making it more common among older adults. The need for early-pancreatic cancer detection diagnostic tools is projected to grow as the world's population ages.

Advances in diagnostic technologies have also played a significant role in the increased demand for pancreatic cancer diagnostics. In recent years, new imaging techniques such as magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), and Ultrasound have been developed that allow for earlier and more accurate detection of pancreatic cancer. These advances have led to an increased demand for these tests and have made it easier for doctors to diagnose pancreatic cancer in its early stages.

The increased need for diagnostic tests is also a result of rising awareness of pancreatic cancer and its symptoms. People requesting diagnostic tests for pancreatic cancer have increased as a result of organizations like the Pancreatic Cancer Action Network and the Lustgarten Foundation raising awareness of the condition and the value of early identification.

Investment in research and development has also played a key role in the increased demand for pancreatic cancer diagnostics. Biotechnology and pharmaceutical companies are investing heavily in the development of new diagnostic tests and treatments for pancreatic cancer, which has led to a growing number of diagnostic options for patients.

In the last three years, there have been several product launches related to pancreatic cancer diagnostics. These products range from new imaging techniques to blood tests that can detect the disease in its early stages.

In 2021, researchers from the University of Michigan developed a new blood test called the Pancreas-Specific Lipase Test (PSLT) that can detect early-stage pancreatic cancer with high accuracy. The test measures the levels of a protein called pancreatic lipase in the blood, which is often elevated in patients with pancreatic cancer. The PSLT has the potential to improve early detection of pancreatic cancer, which is critical in improving patient outcomes.

In 2020, researchers from the University of Virginia School of Medicine developed a new imaging technique called MR-guided Focused Ultrasound (MRgFUS), which uses focused ultrasound waves to destroy cancer cells in the pancreas. The technique is non-invasive and can be performed without the need for surgery or radiation therapy. MRgFUS has the potential to improve the treatment of pancreatic cancer and may offer a less invasive alternative to traditional treatment methods.

Pancreatic cancer diagnostics faces a number of challenges, including the lack of early symptoms, limited diagnostic tools, lack of reliable biomarkers, difficulty in distinguishing between pancreatic cancer and other pancreatic conditions, and the limited effectiveness of current treatment options.

Rising Research and Development related to Pancreatic Cancer

Pancreatic cancer is a highly aggressive cancer that is difficult to diagnose and treat. However, recent research has shown promising developments in the field of pancreatic cancer diagnostics. Liquid biopsy, artificial intelligence, biomarkers, imaging techniques, and personalized medicine are all areas of active research that may ultimately improve patient outcomes in pancreatic cancer.

Liquid biopsy is a non-invasive diagnostic tool that involves the analysis of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) in a patient's blood. Recent research has shown that liquid biopsy can be used to detect pancreatic cancer at an earlier stage than traditional imaging methods.

Artificial intelligence (AI) is being used in the field of pancreatic cancer diagnostics to improve the accuracy and efficiency of existing diagnostic methods. Recent research has shown that AI algorithms can accurately predict the likelihood of pancreatic cancer based on medical imaging data. A study published in the Journal of Clinical Oncology in 2020 found that an AI algorithm was able to predict the likelihood of pancreatic cancer with 90% accuracy based on CT scans.

Biomarkers are biological molecules that can be used to indicate the presence of a disease. Recent research has identified several biomarkers that may be useful in pancreatic cancer diagnostics. A study published in the Journal of Gastroenterology in 2021 found that a combination of three biomarkers (CA19-9, CEA, and FGF21) can accurately predict the likelihood of pancreatic cancer in patients with pancreatic cysts. Another study published in the Journal of Proteome Research in 2020 identified several biomarkers that may be useful in the early detection of pancreatic cancer.

Advances in medical imaging techniques are also improving pancreatic cancer diagnostics. Recent research has shown that endoscopic ultrasound (EUS) is a highly accurate imaging technique for the detection of pancreatic cancer. A study published in the Journal of Gastroenterology in 2020 found that EUS was able to detect pancreatic cancer with 94% accuracy in patients with suspicious pancreatic masses.

Personalized medicine involves tailoring medical treatment to an individual's unique genetic makeup. Recent research has shown that personalized medicine may be useful in pancreatic cancer diagnostics. A study published in the Journal of the National Cancer Institute in 2021 found that a personalized vaccine can stimulate the immune system to attack pancreatic cancer cells.

Growing Prevalence of Pancreatic Cancer

The growing prevalence of pancreatic cancer is likely to have a significant impact on the market for pancreatic cancer diagnostics. As the incidence of pancreatic cancer continues to rise, there is a growing need for better and more efficient diagnostic tools to detect this disease at an early stage when treatment is most effective.

There are several factors driving the increasing prevalence of pancreatic cancer, including an aging population, a growing prevalence of type 2 diabetes, obesity, and unhealthy lifestyle choices like smoking and alcohol use. These developments are anticipated to persist, fueling an increase in demand for pancreatic cancer diagnostics.

In response to this demand, the market for pancreatic cancer diagnostics is likely to grow in the coming years. There are already several diagnostic tools available for pancreatic cancer, including imaging tests like CT scans, MRIs, and PET scans, as well as blood tests that measure levels of certain biomarkers. However, there is still a need for more accurate and reliable diagnostic tools, particularly for early-stage pancreatic cancer.

Research and development efforts are underway to develop new diagnostic tools for pancreatic cancer, such as liquid biopsies that detect circulating tumor DNA in the blood and new imaging technologies that can provide more detailed and accurate images of the pancreas.

The growing prevalence of pancreatic cancer is likely to drive innovation and investment in the market for pancreatic cancer diagnostics as researchers and companies work to develop better tools for detecting and treating this deadly disease, and this will support the growth of global pancreatic cancer diagnostics market in the coming years.

Market Segmentation

Global Pancreatic Cancer Diagnostics Market can be segmented by test type, cancer type, end user, region, and competitive landscape. Based on test type, the market can be divided into Diagnostic Imaging Tests, Biopsy, Blood Tests, Liver Function Tests, and Others. Based on cancer type the market is divided into Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Colloid Carcinoma, and Others. Based on end-user, the market is divided into Hospitals & Clinics, Diagnostic Centers, and Others.

Market Players

Siemens Healthcare GmbH, FUJIFILM Corporation, Laboratory Corporation of America Holdings, Abbott Laboratories, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Immunovia, Inc., are some of the leading players operating in the Global Pancreatic Cancer Diagnostics Market.

Report Scope:

In this report, Global Pancreatic Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Pancreatic Cancer Diagnostics Market, By Test Type:

  • Diagnostic Imaging Tests
  • CT scan
  • MRI
  • Ultrasound
  • Others
  • Biopsy
  • Blood Tests
  • Liver Function Tests
  • Others

Pancreatic Cancer Diagnostics Market, By Cancer Type:

  • Exocrine
  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Colloid Carcinoma
  • Others

Pancreatic Cancer Diagnostics Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

Pancreatic Cancer Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Pancreatic Cancer Diagnostics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pancreatic Cancer Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Diagnostic Imaging Tests, Biopsy, Blood Tests, Liver Function Tests, Others)
      • 5.2.1.1. By Diagnostic Imaging Tests (CT scan, MRI, Ultrasound, Others)
    • 5.2.2. By Cancer Type (Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Colloid Carcinoma, Others)
    • 5.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Product Map
    • 5.3.1. By Test Type
    • 5.3.2. By Cancer Type
    • 5.3.3. By End User
    • 5.3.4. By Region

6. North America Pancreatic Cancer Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Cancer Type
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pancreatic Cancer Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By Cancer Type
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Pancreatic Cancer Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By Cancer Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Pancreatic Cancer Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By Cancer Type
        • 6.3.3.2.3. By End User

7. Europe Pancreatic Cancer Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Cancer Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Pancreatic Cancer Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By Cancer Type
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Pancreatic Cancer Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By Cancer Type
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Pancreatic Cancer Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By Cancer Type
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Pancreatic Cancer Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By Cancer Type
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Pancreatic Cancer Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By Cancer Type
        • 7.3.5.2.3. By End User

8. Asia-Pacific Pancreatic Cancer Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Cancer Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Pancreatic Cancer Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By Cancer Type
        • 8.3.1.2.3. By End User
    • 8.3.2. India Pancreatic Cancer Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By Cancer Type
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Pancreatic Cancer Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By Cancer Type
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Pancreatic Cancer Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By Cancer Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Pancreatic Cancer Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By Cancer Type
        • 8.3.5.2.3. By End User

9. South America Pancreatic Cancer Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Cancer Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Pancreatic Cancer Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By Cancer Type
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Pancreatic Cancer Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By Cancer Type
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Pancreatic Cancer Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By Cancer Type
        • 9.3.3.2.3. By End User

10. Middle East and Africa Pancreatic Cancer Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Cancer Type
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Pancreatic Cancer Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By Cancer Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Pancreatic Cancer Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By Cancer Type
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Pancreatic Cancer Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By Cancer Type
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Pancreatic Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Siemens Healthcare GmbH
    • 15.5.2. FUJIFILM Corporation
    • 15.5.3. Laboratory Corporation of America Holdings
    • 15.5.4. Abbott Laboratories, Inc.
    • 15.5.5. Agilent Technologies, Inc.
    • 15.5.6. Thermo Fisher Scientific Inc.
    • 15.5.7. Immunovia, Inc.

16. Strategic Recommendations